Achieve Life Sciences initiated with a Buy at JonesResearch

JonesResearch initiated coverage of Achieve Life Sciences with a Buy rating and $20 price target. Achieve is a clinical-stage biopharmaceutical company working to develop and commercialize cytisinicline for tobacco cessation, the analyst tells investors in a research note. The firm believes now is the right time for investors to but Achieve in its transition from a clinical to a commercial biopharmaceutical company. The company is seeking potential non-dilutive funding support for a pivotal trial in e-cigarette cessation, which could see a label expansion for cytisinicline in the first half of 2027, according to Jones.